Almotriptan

CLINICAL USE

Acute relief of migraine

DOSE IN NORMAL RENAL FUNCTION

12.5 mg repeated after 2 hours if migraine
recurs (do not take 2nd dose for the same
attack)
Maximum 25 mg in 24 hours

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
469.6 (as malate)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
35

%Excreted unchanged in urine &nbsp &nbsp :
40–50

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
195 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
3.5/7

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 Dose as in normal renal function
10–30 6.25 mg; maximum daily dose
12.5 mg. Use with caution

<10 &nbsp &nbsp &nbsp &nbsp &nbsp :
6.25 mg; maximum daily dose
12.5 mg. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Likely dialysability. Dose as in
GFR <10 mL/min

HDF/high flux &nbsp :
Likely dialysability. Dose as in
GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antidepressants: possibly increased

serotonergic effects with duloxetine;
increased serotonergic effects with St
John’s wort – avoid concomitant use

Antifungals: concentration increased by

ketoconazole (increased risk of toxicity)

Ergot alkaloids: increased risk of

vasospasm

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

Tags: post-by-auto-php